Advanced

A minority-group of renal cell cancer patients with high infiltration of CD20+B-cells is associated with poor prognosis

Sjöberg, Elin; Frödin, Magnus; Lövrot, John; Mezheyeuski, Artur; Johansson, Martin LU ; Harmenberg, Ulrika; Egevad, Lars; Sandström, Per and Östman, Arne (2018) In British Journal of Cancer 119(7). p.840-846
Abstract

Background: The role of B-lymphocytes in solid tumours is unclear. Tumour biology studies have implied both anti- and pro-tumoural effects and prognostic studies have mainly linked B-cells to increased survival. This study aimed to analyse the clinical relevance of B-lymphocytes in renal cell cancer (RCC), where information on the prognostic impact is lacking. Methods: Following immunohistochemistry (IHC) stainings with a CD20 antibody, density of CD20+ B-cells was quantified in an RCC discovery- and validation cohort. Associations of B-cell infiltration, determined by CD20 expression or a B-cell gene-signature, and survival was also analysed in 14 publicly available gene expression datasets of cancer, including the kidney clear cell... (More)

Background: The role of B-lymphocytes in solid tumours is unclear. Tumour biology studies have implied both anti- and pro-tumoural effects and prognostic studies have mainly linked B-cells to increased survival. This study aimed to analyse the clinical relevance of B-lymphocytes in renal cell cancer (RCC), where information on the prognostic impact is lacking. Methods: Following immunohistochemistry (IHC) stainings with a CD20 antibody, density of CD20+ B-cells was quantified in an RCC discovery- and validation cohort. Associations of B-cell infiltration, determined by CD20 expression or a B-cell gene-signature, and survival was also analysed in 14 publicly available gene expression datasets of cancer, including the kidney clear cell carcinoma (KIRC) dataset. Results: IHC analyses of the discovery cohort identified a previously unrecognised subgroup of RCC patients with high infiltration of CD20+ B-cells. The B-cell-high subgroup displayed significantly shorter survival according to uni- and multi-variable analyses. The association between poor prognosis and high density of CD20+ B-cells was confirmed in the validation cohort. Analyses of the KIRC gene expression dataset using the B-cell signature confirmed findings from IHC analyses. Analyses of other gene expression datasets, representing 13 different tumour types, indicated that the poor survival-association of B-cells occurred selectively in RCC. Conclusion: This exploratory study identifies a previously unrecognised poor-prognosis subset of RCC with high density of CD20-defined B-cells.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
British Journal of Cancer
volume
119
issue
7
pages
7 pages
publisher
Nature Publishing Group
external identifiers
  • scopus:85054505901
ISSN
0007-0920
DOI
10.1038/s41416-018-0266-8
language
English
LU publication?
yes
id
0368a061-9648-4ff2-b480-f6a1fc81dc37
date added to LUP
2018-11-13 10:30:17
date last changed
2019-02-20 11:35:22
@article{0368a061-9648-4ff2-b480-f6a1fc81dc37,
  abstract     = {<p>Background: The role of B-lymphocytes in solid tumours is unclear. Tumour biology studies have implied both anti- and pro-tumoural effects and prognostic studies have mainly linked B-cells to increased survival. This study aimed to analyse the clinical relevance of B-lymphocytes in renal cell cancer (RCC), where information on the prognostic impact is lacking. Methods: Following immunohistochemistry (IHC) stainings with a CD20 antibody, density of CD20+ B-cells was quantified in an RCC discovery- and validation cohort. Associations of B-cell infiltration, determined by CD20 expression or a B-cell gene-signature, and survival was also analysed in 14 publicly available gene expression datasets of cancer, including the kidney clear cell carcinoma (KIRC) dataset. Results: IHC analyses of the discovery cohort identified a previously unrecognised subgroup of RCC patients with high infiltration of CD20+ B-cells. The B-cell-high subgroup displayed significantly shorter survival according to uni- and multi-variable analyses. The association between poor prognosis and high density of CD20+ B-cells was confirmed in the validation cohort. Analyses of the KIRC gene expression dataset using the B-cell signature confirmed findings from IHC analyses. Analyses of other gene expression datasets, representing 13 different tumour types, indicated that the poor survival-association of B-cells occurred selectively in RCC. Conclusion: This exploratory study identifies a previously unrecognised poor-prognosis subset of RCC with high density of CD20-defined B-cells.</p>},
  author       = {Sjöberg, Elin and Frödin, Magnus and Lövrot, John and Mezheyeuski, Artur and Johansson, Martin and Harmenberg, Ulrika and Egevad, Lars and Sandström, Per and Östman, Arne},
  issn         = {0007-0920},
  language     = {eng},
  month        = {10},
  number       = {7},
  pages        = {840--846},
  publisher    = {Nature Publishing Group},
  series       = {British Journal of Cancer},
  title        = {A minority-group of renal cell cancer patients with high infiltration of CD20+B-cells is associated with poor prognosis},
  url          = {http://dx.doi.org/10.1038/s41416-018-0266-8},
  volume       = {119},
  year         = {2018},
}